TABLE 1

Clinical characteristics of 17 morbidly obese patients undergoing bypass

Bypass patients (n = 17)
Mean (T0)Mean (3M)Δ
Bypass microarrays (n = 10)
SexFemale
Age (years)43.5 ± 4.10 (29–59)
n = 1041.5 ± 4.0 (23–63)
Height (m)1.60 ± 0.05 (1.52–1.79)
n = 101.60 ± 0.06 (1.59–1.65)
Adipocyte size (μm)98.7 ± 1.2 (78.9–107.2)83.3 ± 1.3 (70.8–95)15.4*
n = 1094.7 ± 2.53 (77.76–107)83.8 ± 2.59 (66.03–94.69)10.63
Weight (kg)128.2 ± 2.4 (92.3–164.4)106.1 ± 2.6 (80.0–143.0)−22.1*
n = 10123.1 ± 1.6 (96.2–148.8)104.5 ± 1.7 (79.5–130.9)18.53
Fat mass (kg)65.15 ± 3.549.65 ± 2.80−15.5
n = 1067.33 ± 4.0351.38 ± 3.5412.44
BMI (kg/m2)48.0 ± 6.8 (33.0–57.1)39.7 ± 6.8 (28.7–53.0)−8.3*
n = 1047.6 ± 4.3 (43.0–57.0)40.6 ± 4.9 (34.0–49.0)7.02
Glucose (mg/ml)1.00 ± 0.040.91 ± 0.02−0.09
n = 100.99 ± 0.070.90 ± 0.040.09
Insulin (μU/ml)14.2 ± 2.212.8 ± 3.11.44
n = 1012.8 ± 3.57.2 ± 1.15.61
QUICKI0.34 ± 0.040.37 ± 0.040.03
n = 100.33 ± 0.020.37 ± 0.020.04
Leptin (ng/ml)49.7 ± 6.730.9 ± 5.6−18.8
n = 1051.9 ± 3.431.0 ± 4.120.93
SAA (μg/ml)35.03 ± 9.515.86 ± 3.1−19.16
n = 1035.15 ± 10.1312.62 ± 3.522.53
ORO (g/l)0.94 ± 0.030.90 ± 0.04−0.03
n = 101.03 ± 0.050.87 ± 0.050.16
CRP (μg/ml)13.0 ± 11.15.0 ± 3.2−8.0
n = 1030.0 ± 9.65.6 ± 1.124.33
  • Data are means ± SE (range). Metabolic and clinical parameters at baseline (T0) and 3 months after bypass (3M). Δ = strength of clinical or biological changes before versus after surgery. Values in italics are clinical features of 10 morbidly obese subjects (of the 17 collected) whose scWAT was processed for microarray gene expression before/after surgery-induced weight loss. QUICKI, quantitative insulin sensitivity check index.

  • *

    * P < 0.001,

  • P < 0.01,

  • P < 0.05.